Japan all-in on iPS cells but where's the payoff?
This article was originally published in Clinica
The citizens of Japan are early adopters when it comes to new technology. Products are acquired and embraced until the next big thing comes along, with advertising campaigns often focusing on the benefits of small incremental improvements.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.